AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - Press Release)
Results of three studies show the oral anti-diabetic agent Actos (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases, and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline. These studies also showed that, in addition to increasing low-density lipoprotein cholesterol particle size, Actos can significantly increase the size and buoyancy of HDL particles. The findings were presented at the 13th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists…